Nature Reviews Drug Discovery
Nature Portfolio · General Science & Medicine · ISSN 1474-1776, 1474-1784
- Impact (2-yr)
- 15.1
- h-index
- 484
- Open access
- 13%
- Works
- 6.9K
- Papers this month
- 11
Rebuilt
Moved this week
AI in drug discovery has shown limited clinically relevant impact despite decades of development, highlighting the need for improved translational focus.
- 7 cites
Latest in Nat Rev Drug Discov
Newest first · last 60 days
Simulation-guided clinical trial design enhances decision-making and accelerates drug development by optimizing complex adaptive strategies.
Targeting T follicular helper cells offers potential for lifelong health by modulating immune responses across various diseases and aging processes.
Innovative delivery systems and formulations are key to advancing mRNA therapeutics 2.0, enabling repeated administration and targeted organ delivery beyond the liver.
Soft drugs are deliberately designed to undergo rapid metabolic inactivation, enhancing safety while maintaining efficacy, with notable success in topical applications.
Cell surface RNA-binding proteins are emerging as potential biomarkers and immunotherapy targets, with specificities linked to cell type and disease, including cancer.
Selective targeting of IL-6 trans-signalling pathway offers potential for safer, more precise therapies, as it accounts for distinct roles in disease and homeostasis.
The drug target landscape has expanded to include 686 biomolecules modulated by 1,702 drugs over the past 25 years, reflecting significant advances in discovery methods.
Pharmacological strategies targeting multiple cellular pathways show promise in combating sarcopenia, a major cause of frailty in aging populations, with recent clinical trials indicating progress.
Mechanistic insights into agonistic antibodies could unlock their full potential in cancer and autoimmune therapies, with recent advances promising improved safety and efficacy.
Dysregulated solute carrier (SLC) transporters are emerging as promising therapeutic targets for CNS disorders, with many linked to epilepsy, neurodegeneration, and autism.
Targeting claudins offers a promising new approach, with zolbetuximab becoming the first FDA-approved CLDN-18.2-targeted antibody for gastric cancer treatment.
Autophagy plays a complex, dual role in cancer, supporting tumor survival and immune responses, making it a challenging but promising therapeutic target.
- 1 cites
Precision psychiatry leverages biomarkers to improve treatment targeting, with initial success in stratified trials for postpartum depression and schizophrenia.
Targeting transcriptional CDKs offers promising therapeutic potential, with over 15 years of research revealing their critical role in gene regulation and cancer vulnerabilities.
AI in drug discovery has shown limited clinically relevant impact despite decades of development, highlighting the need for improved translational focus.
- 7 cites
Follow Nat Rev Drug Discov in the app
Browse JClub
Journals this month
- bioRxiv5569
- medRxiv1746
- Environ Res483
- PNAS463
- Sci Adv439
- JAMA255
- Cell Rep210
- BMJ199
- Nat Commun177
- Environ Pollution170
- Lancet149
- Science138
- NEJM119
- Applied & Environ Microbio116
- J Exp Bot115
- Curr Biol112
- mBio109
- Nature104
Moving areas, week to 3 Oct 2026
- Single-cell and spatial transcriptomics10
- Artificial Intelligence in Healthcare and Education8
- CAR-T cell therapy research7
- Neuroinflammation and Neurodegeneration Mechanisms6
- Lung Cancer Treatments and Mutations5
- Diabetes Treatment and Management4
- Pancreatic and Hepatic Oncology Research4
- Photosynthetic Processes and Mechanisms4
- Genomics and Chromatin Dynamics4
- Gut microbiota and health4